AstraZeneca Pharma India Limited and Mankind Pharma Limited entered into an agreement for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate (inhaled
corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license. Globally AstraZeneca is an established leader in respiratory care, a disruptor in immunology and will continue to transform care for some of the most debilitating and chronic respiratory and immune-mediated diseases. With an ambition to transform Respiratory & Immunology care for patients in India, moving beyond symptom control to disease modification, remission and, one day, cure, AstraZeneca India is focused to be number 1 in respiratory Biologics. AstraZeneca is present in therapy areas including Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease in India and is focused on transforming the future of healthcare by unlocking the power of what science can do for people, society and planet.